Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV

Completed · Phase 1

Conditions studied: HIV/AIDS

In brief

HIV has transformed into a chronic illness due to the advent of effective treatments in the absence of a cure. As a result, the prevalence of non-AIDS defining cancers (NADCs), including lung cancer, has increased three-fold among people living with HIV. NADCs now account for 50% of all cancers among the people. Smoking is one of the major contributing factors to lung cancer and smoking prevalence is substantially higher in this population than the general U.S. population. Smoking prevalence does not differ by gender among people living with HIV. Women of color, particularly African American women represent the majority of women living with HIV (WLHIV) followed by Latinas. WLHIV smoke at a rate almost 3 times higher than that for the general U.S. female population (e.g., 42% vs. 16%). The proposed study has two phases: 1) the development of a storytelling narrative communication (SNC) intervention that will be added to an established HIV-tailored smoking cessation intervention and 2) a two-arm randomized controlled trial (RCT) of the HIV-tailored intervention plus the SNC Intervention compared with the HIV-tailored intervention only. The investigators will develop narrative videos with three to five WLHIV who will be talking about their personal struggles with smoking and success in quitting. Preliminary study revealed that the established HIV-tailored intervention was effective only for short-term (≤ 2 months) abstinence. Many relapsed to smoking between the 2nd and 6th month of quitting. The investigators propose that the SNC intervention will be an effective strategy to sustain their quit efforts for long-term abstinence (≥ 6 months). A total of 60 WLHIV will be recruited and randomly assigned to either the experimental arm (a combination of HIV-tailored and SNC interventions) or the control arm (HIV-tailored intervention only). Specific aims of the study are to 1) Identify SNC intervention components that are rated high in transport and identification for use as an enhancement to an HIV-tailored smoking cessation intervention; 2) Determine the feasibility and acceptability of the SNC intervention for WLHIV by assessing the rate of recruitment and retention for feasibility and the degree of transport and identification for acceptability; and 3) Establish an effect size of HIV-tailored and SNC interventions for smoking cessation in comparison with the HIV-tailored smoking cessation intervention only for WLHIV, for subsequent grant applications.

Key facts

Study ID: NCT03289676
Run by: University of Massachusetts, Boston
People needed: 53
Starts: 2017-09-06
Expected to finish: 2018-11-01
Last updated by the study team: 2019-09-09

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: accepted.

You may qualify if…

women who:
are able to speak English
self-report HIV infection and submit a supplementary document if necessary
are between the ages of 18 and 65
have been smoking at least 5 cigarettes a day for the past 6 months
own a mobile phone with an access to a video call application such as Skype, Imo, Tango, and Face Time
are willing to quit smoking within the next 4 weeks from the baseline assessment; and
agree to use an approved form of birth control (e.g., oral medications, condoms, and intrauterine devices) during the study period.

You may not qualify if…

Women who:
are not able to speak English
are pregnant or lactating
have an active skin disease or serious alcohol use problems (≥ 26 on the Alcohol Use Disorders Identification Test59)
self-report currently receiving treatment for a serious mental illness (e.g., schizophrenia and bipolar disorder) or
currently use any illegal substances excluding marijuana.

Where it is running

University Massachusetts Boston — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.